Levels of 0.40% or higher are potentially fatal, with risks including coma and death due to respiratory arrest
A method for preventing radiation-induced ototoxicity in an individual in need thereof comprising intratympanic administration of a pharmaceutical composition comprising a therapeutic agent selected from a JNK inhibitor, TRPV modulator, an MET channel inhibitor, and an otoprotectant to the individual in need thereof, wherein the pharmaceutical composition is administered prior to onset of radiation therapy, and wherein the composition provides sustained release of the therapeutic agent into the ear for a period of at least 5 days after a single administration
We work with you to determine the optimal dosage and delivery method for your specific situation, ensuring that your BPC-157 therapy aligns perfectly with your wellness goals
These findings suggest that HR samples are unlikely to be homogeneous in terms of glutamatergic metabolism and further attention to the distinction between genetic and clinical HR is warranted
Life Extension third-party tests its raw materials, too, and Quicksilver performs one of the largest allergy panels we've encountered
Psychosomatics 27 , 6566 (1986)
